Described herein are therapeutic approaches with immune modifiers of the Th2 pathway for the treatment of allergic and inflammatory diseases. Aspects of the disclosure relate to methods for decreasing Th2-type cell responses in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an anti-Dectin-1 antibody or antigen binding fragment thereof operatively linked to a TLR agonist.
